Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nu-Med PlusNUMD +21.05% Equity-to-Asset is -41.00 as of Mar. 2026. The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Nu-Med Plus ranks worse than 99.77% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Nu-Med Plus's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.29 Mil. Nu-Med Plus's Total Assets for the quarter that ended in Mar. 2026 was $0.01 Mil.
The historical rank and industry rank for Nu-Med Plus's Equity-to-Asset or its related term are showing as below:
NUMD'
s Equity-to-Asset Range Over the Past 10 Years
Min: -123.31 Med: -3.37 Max: 0.84
Current: -41
During the past 13 years, the highest Equity to Asset Ratio of Nu-Med Plus was 0.84. The lowest was -123.31. And the median was -3.37.
NUMD's Equity-to-Asset is ranked worse than 99.77% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs NUMD: -41.00
Nu-Med Plus (OTCPK:NUMD) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Nu-Med Plus Equity-to-Asset Related Terms
Nu-Med Plus Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Nu-Med Plus's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUMD vs SSKN, ODYY, NUWE: Equity-to-Asset Comparison
For the Medical Devices subindustry, Nu-Med Plus's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nu-Med Plus Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Nu-Med Plus's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Nu-Med Plus's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nu-Med Plus (NUMD) has a Equity-to-Asset of -41.00 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Nu-Med Plus and its competitors. According to the industry distribution chart, Nu-Med Plus ranks #851 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 99.8%.
Is Nu-Med Plus' Equity-to-Asset too high?
Nu-Med Plus' current Equity-to-Asset is -41.00. Based on the distribution chart, Nu-Med Plus ranks #851 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Nu-Med Plus' Equity-to-Asset compare to SSKN and ODYY?
According to the Medical Devices & Instruments industry distribution chart, Nu-Med Plus ranks #851 out of 853 companies for Equity-to-Asset. This places Nu-Med Plus in the lower half of its industry. The industry median Equity-to-Asset is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Nu-Med Plus and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nu-Med Plus's current Equity-to-Asset is -41.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nu-Med Plus stock overvalued right now?
Nu-Med Plus (NUMD) has a current Equity-to-Asset of -41.00. The current Equity-to-Asset is -41.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Nu-Med Plus (NUMD), the current Equity-to-Asset is -41.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nu-Med Plus Inc is a medical device company engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems, and the medical community throughout the world. It is currently working to locate a merger partner that will be able to fund the final development of these products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUMD has been successfully added to your 
